//•指数的低迷并未完全覆盖板块内部的差异；•药捷安康过去三个月的区间涨幅达384.32%，其核心产品针对胆管癌、前列腺癌等多个适应症开展了单药/联合治疗的临床开发项目；•康方生物、信达生物继5~7月大涨后迎来回调。过去三个月（8月1日~10月31日），备受资金关注的创新药板块进入持续调整通道，恒生生物科技指数区间涨幅-7%，中华香港生物科技指数区间涨幅-5.86%。研发客根据Choice数据统计...
Source Link//•指数的低迷并未完全覆盖板块内部的差异；•药捷安康过去三个月的区间涨幅达384.32%，其核心产品针对胆管癌、前列腺癌等多个适应症开展了单药/联合治疗的临床开发项目；•康方生物、信达生物继5~7月大涨后迎来回调。过去三个月（8月1日~10月31日），备受资金关注的创新药板块进入持续调整通道，恒生生物科技指数区间涨幅-7%，中华香港生物科技指数区间涨幅-5.86%。研发客根据Choice数据统计...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.